Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 12;14(8):1937.
doi: 10.3390/cancers14081937.

In Search of the Appropriate Anticoagulant-Associated Bleeding Risk Assessment Model for Cancer-Associated Thrombosis Patients

Géraldine Poénou  1 , Emmanuel Tolédano  1   2 , Hélène Helfer  1 , Ludovic Plaisance  1 , Florent Happe  1 , Edouard Versini  1   2 , Nevine Diab  1   2 , Sadji Djennaoui  1 , Isabelle Mahé  1   2   3   4
Affiliations
Review

In Search of the Appropriate Anticoagulant-Associated Bleeding Risk Assessment Model for Cancer-Associated Thrombosis Patients

Géraldine Poénou et al. Cancers (Basel). .

Abstract

Patients with venous thromboembolism events (VTE) in the context of cancer should receive anticoagulants as long as the cancer is active. Therefore, a tailor-made anticoagulation strategy should rely on an individualized risk assessment model (RAM) of recurrent VTE and anticoagulant-associated bleeding. The aim of this review is to investigate the applicability of the currently available RAMs for anticoagulant-associated bleeding after VTE in the CAT population and to provide new insights on how we can succeed in developing a new anticoagulant-associated bleeding RAM for the current medical care of CAT patients. A systematic search for peer-reviewed publications was performed in PubMed. Studies, including systematic reviews, were eligible if they comprised patients with VTE and used a design for developing a prediction model, score, or other prognostic tools for anticoagulant-associated bleeding during anticoagulant treatment. Out of 15 RAMs, just the CAT-BLEED was developed for CAT patients and none of the presented RAMs developed for the VTE general population were externally validated in a population of CAT patients. The current review illustrates the limitations of the available RAMs for anticoagulant-associated bleeding in CAT patients. The development of a RAM for bleeding risk assessment in patients with CAT is warranted.

Keywords: bleeding; cancer associated thrombosis; risk assessment model.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of the study selection.
See this image and copyright information in PMC

References

    1. Blom J.W., Doggen C.J., Osanto S., Rosendaal F.R. Malignancies, Prothrombotic Mutations, and the Risk of Venous Thrombosis. JAMA. 2005;293:715. doi: 10.1001/jama.293.6.715. - DOI - PubMed
    1. Lee A.Y., Levine M.N., Baker R.I., Bowden C., Kakkar A.K., Prins M., Rickles F.R., Julian J.A., Haley S., Kovacs M.J., et al. Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer. N. Engl. J. Med. 2003;349:146–153. doi: 10.1056/NEJMoa025313. - DOI - PubMed
    1. Mulder F.I., van Es N., Kraaijpoel N., Di Nisio M., Carrier M., Duggal A., Gaddh M., Garcia D., Grosso M.A., Kakkar A.K., et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study. Thromb. Res. 2020;185:13–19. doi: 10.1016/j.thromres.2019.11.007. - DOI - PubMed
    1. McBane R.D., 2nd, Wysokinski W.E., Le-Rademacher J.G., Zemla T., Ashrani A., Tafur A., Perepu U., Anderson D., Gundabolu K., Kuzma C., et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J. Thromb. Haemost. 2020;18:411–421. doi: 10.1111/jth.14662. - DOI - PubMed
    1. Agnelli G., Becattini C., Bauersachs R., Brenner B., Campanini M., Cohen A., Connors J.M., Fontanella A., Gussoni G., Huisman M.V., et al. Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study. Thromb. Haemost. 2018;118:1668–1678. doi: 10.1055/s-0038-1668523. - DOI - PubMed

LinkOut - more resources